AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05121233
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a single dose 75 mg IV diclofenac by infusion prior to the procedure
Trial: NCT05121233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose iv placebo (saline ) by infusion prior to the procedure
Trial: NCT04768179
Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
Trial: NCT05435638
Drug: KM-001 1% cream 12 weeks treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Trial: NCT05435638
Drug: KM-001 1% cream 16 weeks treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Trial: NCT04771897
Drug: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Trial: NCT06031012
Drug: CGECC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received CGECC alone from the beginning of radiotherapy to one week after radiotherapy.
Trial: NCT06219473
Drug: subepithelial connective tissue graft
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
Trial: NCT05072314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only
Trial: NCT05544734
Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab
RxNorm normalized name: HYDROCODONE 5MG/ACETAMINOPHEN 325MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/325 mg tablet
Trial: NCT05544734
Drug: Acetaminophen 1000mg
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablet
Trial: NCT05544734
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg tablet
Trial: NCT05007873
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06574048
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline bolus
Trial: NCT06134375
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
Trial: NCT05528588
Drug: Diuretic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive home dose oral furosemide or oral furosemide per standard of care.
Trial: NCT04599634
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with 650mg acetaminophen 30-60 minutes prior to obinutuzumab doses.
Trial: NCT04792567
Drug: BAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken orally once per day (dose depends on CYP2C9 genotype)
Trial: NCT04792567
Drug: Baseline disease modifying therapies (DMTs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
Trial: NCT05629585
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active Comparator. Tablet. Oral route of administration
Trial: NCT06392295
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy will be administered as per standard of care.
Trial: NCT06392295
Drug: Androgen Receptor Signaling Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
Trial: NCT05108571
Drug: DA-5210 10/1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05678933
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Trial: NCT06350630
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
Trial: NCT06511349
Drug: YOLT-203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IP is administered intravenously at the predetermined dose.
Trial: NCT05214495
Drug: topical oral Omega-3 hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral Omega-3 hydrogel prepared from fish oil
Trial: NCT05214495
Drug: conventional preventive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)
Trial: NCT05061732
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g bid
Trial: NCT05061732
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1g bid
Trial: NCT05061732
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g qid
Trial: NCT05683340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, tablet, once daily, for 12 weeks
Trial: NCT06359002
Drug: BYON4413
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYON4413 will be administered by IV infusion.
Trial: NCT05293249
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
Trial: NCT05931367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04883931
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
Trial: NCT06008860
Drug: Experimental: Primary Cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
Trial: NCT06143956
Drug: LY3305677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Trial: NCT06143956
Drug: LY3841136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Trial: NCT05624528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill that contains no medicine
Trial: NCT02579187
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
Trial: NCT06158516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Trial: NCT02579187
Drug: 5µg of pSil-miR200c and 5µg of PMIS miR200a
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
Trial: NCT06642441
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
Trial: NCT05237284
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet oral
Trial: NCT05237284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05983445
Drug: genakumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg s.c.
Trial: NCT05983445
Drug: placebo for genakumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c.
Trial: NCT05983445
Drug: Diprospan
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7mg i.m.
Trial: NCT05575180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT05196035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to finerenone, treatment duration will be 180±7 days
Trial: NCT05053165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects will be randomized to receive placebo once daily orally
Trial: NCT06419374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06532630
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
Trial: NCT06458010
Drug: YOLT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IP is administered intravenously at the predetermined dose.
Trial: NCT05516758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06772584
Drug: Ginkgobiloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group s take it as treatment of deep sleep in nectornal enuresis
Trial: NCT06482892
Drug: TP03HN106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia.
Trial: NCT06200779
Drug: Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Described in Arms section
Trial: NCT06200779
Drug: PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
Trial: NCT05280782
Drug: Ga-68 Galmydar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
Trial: NCT05062356
Drug: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
RxNorm normalized name: epinephrine 1:200,000 / prilocaine HCl 4 % 1.8 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10cc
Trial: NCT05062356
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg
Trial: NCT05092646
Drug: Drug/Placebo: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug/Placebo: 0.9% Normal Saline
Trial: NCT04700826
Drug: Direct Oral Anticoagulants
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
Trial: NCT06280690
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGM-101 is cea-targeted fluorescent dye
Trial: NCT06004128
Drug: VYD222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody
Trial: NCT05797558
Drug: Medical treatment (eplerenone)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
Trial: NCT05948475
Drug: Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
Trial: NCT04821648
Drug: RJV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection in the abdomen
Trial: NCT04821648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
Trial: NCT05602064
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
Trial: NCT05427383
Drug: KN026/Placbo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV KN026/Placebo at 30 mg/kg on D1, Q3W
Trial: NCT06368167
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554
Trial: NCT05082376
Drug: CLM Original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05123820
Drug: Treatment period A
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Trial: NCT05123820
Drug: Treatment period B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Trial: NCT05508009
Drug: Cyclophosphamide 1200 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
Trial: NCT05508009
Drug: Cyclophosphamide 100 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
Trial: NCT05340725
Drug: DEX-IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
Trial: NCT05340725
Drug: DEX-Rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Trial: NCT05340725
Drug: DEX-Nano-Rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Trial: NCT05269381
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05687890
Drug: Placebo of SC0062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Trial: NCT05794165
Drug: Thrombate infusion
RxNorm normalized name: Thrombate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Trial: NCT05794165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Trial: NCT05687890
Drug: SC0062 medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Trial: NCT05330182
Drug: LMN-201
RxNorm normalized name: NUTRITION SUPL TRAUM-AID HBC/LMN PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
Trial: NCT06236672
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 RA initiated between January 2019 and December 2022
Trial: NCT02393482
Drug: Estroprogestinic therapy (Etinil-estradiol/levonorgestre)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
Trial: NCT02393482
Drug: Gonadotropin-releasing hormone agonist (Leuprorelin acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (3,75 mg/2 ml)/month
Trial: NCT00000941
Drug: Pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000941
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05136755
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT06091085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
Trial: NCT04452851
Drug: COPD Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler medication to support quick relief from COPD symptoms
Trial: NCT05266768
Drug: IBI346
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Trial: NCT06307925
Drug: HC010
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HC010 Q2W/28d intravenous infusion
Trial: NCT05534321
Drug: Standard of care systemic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.